267 related articles for article (PubMed ID: 33688024)
1. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
[TBL] [Abstract][Full Text] [Related]
2. Resource use and cost of hepatitis C-related care.
Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
[TBL] [Abstract][Full Text] [Related]
3. Disease burden of chronic hepatitis B among immigrants in Canada.
Wong WW; Woo G; Heathcote EJ; Krahn M
Can J Gastroenterol; 2013 Mar; 27(3):137-47. PubMed ID: 23516678
[TBL] [Abstract][Full Text] [Related]
4. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
5. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
7. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
8. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
[TBL] [Abstract][Full Text] [Related]
9. Burden of disease and cost of chronic hepatitis C infection in Canada.
Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
[TBL] [Abstract][Full Text] [Related]
10. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
11. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico.
Méndez-Sánchez N
Ann Hepatol; 2012; 11(4):550-1. PubMed ID: 22700637
[No Abstract] [Full Text] [Related]
12. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
[TBL] [Abstract][Full Text] [Related]
13. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.
Rein DB; Borton J; Liffmann DK; Wittenborn JS
Hepatology; 2016 Apr; 63(4):1135-44. PubMed ID: 26707033
[TBL] [Abstract][Full Text] [Related]
14. Economic Burden of Hepatitis C Infection.
Stepanova M; Younossi ZM
Clin Liver Dis; 2017 Aug; 21(3):579-594. PubMed ID: 28689595
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
[TBL] [Abstract][Full Text] [Related]
16. Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study.
Mendlowitz A; Bremner KE; Walker JD; Wong WWL; Feld JJ; Sander B; Jones L; Isaranuwatchai W; Krahn M
CMAJ Open; 2021; 9(3):E897-E906. PubMed ID: 34584004
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan.
Fukuda H; Yano Y; Sato D; Ohde S; Noto S; Watanabe R; Takahashi O
Pharmacoeconomics; 2020 Mar; 38(3):297-306. PubMed ID: 31761994
[TBL] [Abstract][Full Text] [Related]
18. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
19. [Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].
Liang S; Zhang SX; Ma QS; Xiao HW; Lü QY; Xie X; Mei SJ; Hu DS; Zhou BP; Li B; Chen JF; Cui FQ; Wang FZ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1340-5. PubMed ID: 21223660
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
